Research programme: age-related macular degeneration therapy - Medigene AGAlternative Names: EndoGreen
Latest Information Update: 30 Aug 2010
At a glance
- Originator MediGene AG
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Age-related macular degeneration
Most Recent Events
- 15 Mar 2007 Preclinical trials in Age-related macular degeneration in Germany (unspecified route)
- 15 Mar 2007 EndoGreen is available for licensing worldwide (http://www.medigene.com)